SOFW SOFWAVE MEDICAL LTD

Dr. Kavita Darji Wins the Drs. Alastair and Jean D. Carruthers Award at ASDS 2024 for Sofwave SUPERB™ Abstract

Dr. Kavita Darji Wins the Drs. Alastair and Jean D. Carruthers Award at ASDS 2024 for Sofwave SUPERB™ Abstract

Abstract entitled, “Safety and Efficacy of Synchronous Ultrasound Parallel Beam Technology to Lift the Upper Lip and Improve Perioral Rhytids” selected as the highest rated Cosmetic Dermatologic Surgery Fellow Research Abstract

SAN CLEMENTE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced Kavita Darji, MD, FAAD, board-certified dermatologist and cosmetic dermatologic surgeon who completed her ASDS-accredited cosmetic dermatologic surgery fellowship, was selected as the winner of the . The award is given to the highest rated Cosmetic Dermatologic Surgery Fellow Research Abstract for 2024. The award and abstract entitled, “Safety and Efficacy of Synchronous Ultrasound Parallel Beam Technology to Lift the Upper Lip and Improve Perioral Rhytids” were presented during the which took place from October 17th through the 20th in Orlando, Florida.

Kavita Darji, MD, the study’s author noted, “As a graduated ASDS accredited research fellow, I am incredibly grateful to have received this accolade from an esteemed panel of industry peers at ASDS. As people age, the production and density of elastin decreases, which can lead to wrinkles and skin laxity. The study’s interim analysis highlighted the fact that in just two treatments, 93% of patients’ appearance improved at the 1- and 3-month period. Moreover, the treatment effect remained in 58% of the subjects at six months after treatment. In the same way, an impressive 85% of subjects also noted a remarkable improvement in their own appearance at the 6-month period after the last treatment. The results truly place an industry spotlight on the effectiveness of Sofwave’s SUPERB™ ultrasound technology - a next-generation device to easily target the mid-dermis in order to maximize new collagen production and skin elasticity.”

Louis Scafuri, Sofwave CEO, noted, “We commend Dr. Darji for her efforts to further add to Sofwave’s clinical body of research. We believe that our treatments represent the future of non-invasive skin regeneration and the growth in the interest of our treatments and devices is an encouraging sign of market acceptance.”

Interim Analysis Results Highlighted in the Study

  • Patients’ results were measured in accordance with the Physician Global Aesthetic Improvement Scale (PGAIS).
  • Following the first treatment, 36% of the subjects had an improvement according to the study investigators assessments and in accordance with the PGAIS.
  • This rate increased to 93% at 1- and 3-month following the second treatment (at FU1 and FU2, respectively). The treatment effect remained at most of the subjects (58%) also six months after treatment (FU3).



The study remains ongoing.

The Drs. Alastair and Jean D. Carruthers Award is given annually and was designed by the ASDS Accreditation Work Group to stimulate interest and acknowledge cosmetic research contributions of Fellows of ASDS-accredited fellowship programs.

About Sofwave Medical

 has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology, is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin), to improve the appearance of skin laxity on the upper arms, as well as the short-term improvement in the appearance of cellulite and treatment of acne scars. The company’s Pure Impact™ module uses EMS technology and is cleared for muscle toning. Sofwave’s products provide physicians with smart yet simple, effective, and safe aesthetic solutions for their patients. Contact: 

Investor Contact:

Brian Ritchie

LifeSci Advisors LLC

(212) 915-2578

A photo accompanying this announcement is available at



EN
22/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SOFWAVE MEDICAL LTD

 PRESS RELEASE

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Ful...

Sofwave Medical Reports Preliminary, Unaudited, Fourth Quarter and Full Fiscal Year 2025 Topline Financial Results SAN CLEMENTE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced preliminary financial results for the fourth quarter and full fiscal year, for the period ended December 31, 2025. Preliminary Financial Results Fourth quarter 2025 revenue is expected to total between $28.6 million and $28.9 million, as compared to approximately $1...

 PRESS RELEASE

Sofwave Medical Reports Third Quarter 2025 Financial Results and Busin...

Sofwave Medical Reports Third Quarter 2025 Financial Results and Business Highlights —  Record quarterly revenue in third quarter of $21.1M, +56% year-over-year growth; IFRS gross margin of 73.7%  — Third quarter pulse recurring revenue of $8.3M, +55% year-over-year growth — First nine months revenue of $58.7M, +42% year-over-year growth; IFRS gross margin of 75.1% — First nine months IFRS and non-IFRS net income of $1.4M and $3.2M, respectively, versus a net loss of $3.8M and $2.1M, respectively, in the same year ago period — Approximately 667,00 pulse treatments administered...

 PRESS RELEASE

Sofwave to Participate in Upcoming November Investor Conferences

Sofwave to Participate in Upcoming November Investor Conferences SAN CLEMENTE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that management will participate in the following investor conferences: Stifel 2025 Healthcare ConferencePresentation Format: Corporate overviewPresentation Date: Wednesday, November 12, 2025Presentation Time: 10:40 a.m. ETWebcast: Jefferies London Healthcare Conference Presentation Format: Corporate overviewPresentation Date: ...

 PRESS RELEASE

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit

Sofwave to Participate in the Jefferies Virtual Private MedTech Summit SAN CLEMENTE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Jefferies Virtual Private MedTech Summit on October 1st, 2025. About Sofwave Medical has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology...

 PRESS RELEASE

Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Stand...

Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Standalone EMS Device For Comprehensive Multi-Body Area Muscle Strengthening and Firming The Pure Impact VIP™ standalone device represents a major extension of the Pure Impact™ product line and introduces an all-in-one independent unitStandalone device is launched with an enhanced Pure Impact™ feature set which provides comprehensive muscle strengthening programs that focus on multiple body areas including the: abdomen, arms, thighs, and buttocks and enables simultaneous treatment of 6 muscle groupsIn the recent McKinsey Life ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch